Sellas Life Sciences Group

SLS · United States

Share price · SLS

$17.95+4.85 (+37.02%) 3M

close as of 2026-11-18 · 24h delayed · vol 35.8M (3.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SLS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026+156.4%
  2. 28 Oct 2026-14.7%
  3. 20 Oct 2026+14.2%
  4. 11 Sep 2026-14.4%
  5. 21 Aug 2026+15.4%
  6. 29 Jun 2026+24.7%
  7. 26 Jun 2026+17.7%
  8. 25 Jun 2026+14.8%
  9. 21 May 2026-15.7%
  10. 20 May 2026+18.2%

Share of unusual movement by asset

For each asset, the share of SLS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
WT1 (Wilms Tumor-1 protein)Vaccine
Acute Myeloid LeukemiaMultiple Myeloma
Phase 1/2
CDK9Small molecule
Acute Myeloid Leukemia
Phase 1
GPNMBAntibody–drug conjugate
Non-Small Cell Lung CancerAcute Myeloid Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
TambiciclibPhase 1/2Hematologic Malignancies
Est. primary completion 2026-12-30 · NCT04588922 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026Topline resultGalinpepimut-SPhase 3 REGAL topline: overall survival primary endpoint met

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$7.0M$135M$10M-$5.9M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$6.3M$138M$9.6M-$7.6M operating cash flowreport ↗
2026-Q1—$5.1M$107M$8.4M-$8.8M operating cash flowreport ↗
2025-Q3—$4.2M$44M$6.8M-$7.1M operating cash flowreport ↗
2025-Q2—$3.9M$25M$6.6M-$7.3M operating cash flowreport ↗
2025-Q1—$3.2M$29M$5.8M-$9.1M operating cash flowreport ↗
2024-Q3—$4.4M$21M$7.1M-$7.8M operating cash flowreport ↗
2024-Q2—$5.2M$9.3M$7.5M-$9.7M operating cash flowreport ↗
2024-Q1—$5.1M$19M$9.6M-$11M operating cash flowreport ↗
2023-Q3$0$5.8M$4.1M$9.3M-$6.9M operating cash flowreport ↗
2023-Q2$0$5.9M$14M$8.8M-$7.6M operating cash flowreport ↗
2023-Q1$0$7.2M$24M$11M-$12M operating cash flowreport ↗
2022-Q3$0$4.3M$21M$7.0M-$5.8M operating cash flowreport ↗
2022-Q2$0$5.5M$27M$8.4M-$5.8M operating cash flowreport ↗
2022-Q1$1.0M$4.6M$14M$17M-$7.2M operating cash flowreport ↗
2021-Q3$0$4.5M$26M$7.1M-$5.9M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$16M$72M$6.7M-$28M operating cash flowreport ↗

Sellas Life Sciences Group reported no disclosed revenue for fiscal year 2025. R&D spend was $16.02M, down 16.1% YoY, with cash and equivalents of $71.89M, a net loss of $26.86M, and quarterly net burn of $26.86M.

The filing focuses on clinical development rather than financial guidance. The Phase 3 REGAL trial of galinpepimut-S in AML maintenance continues, with 72 pooled events reported as of December 26, 2025 and final analysis planned at 80 events. The Phase 2 trial of SLS009 in relapsed/refractory AML met its primary endpoints, and FDA guidance supported advancement into a randomized 80-patient first-line study that began enrollment in Q1 2026. The company also entered an agreement with IMPACT-AML for European evaluation of SLS009 and remains in arbitration with 3D Medicines regarding milestone payments.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$19M$14M$7.7M-$35M operating cash flowreport ↗
2023-FY$0$24M$2.6M$9.3M-$31M operating cash flowreport ↗
2022-FY$1.0M$20M$17M$10M-$24M operating cash flowreport ↗
2021-FY$7.6M$16M$21M$5.2M-$26M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-16Stergiou Angelos M. · director, President and CEOAward / grant1,065,000——Form 4
2026-01-07Wasman Jane · directorAward / grant50,000——Form 4
2026-01-07Kalin Katherine Bach · directorAward / grant50,000——Form 4
2026-01-07Burns John Thomas · CFOAward / grant300,000——Form 4
2026-01-07CICIC DRAGAN · SVP, Chief Development OfficerAward / grant300,000——Form 4
2026-01-07SCHEINBERG DAVID A · directorAward / grant50,000——Form 4
2026-01-07VAN NOSTRAND ROBERT L · directorAward / grant50,000——Form 4
2026-01-07Varian John · directorAward / grant50,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 157 reporting institutions held 53.9M shares ($224.3M, 26.7% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.12,198,410$51.6M
2STATE STREET CORP8,396,356$35.5M
3VANGUARD CAPITAL MANAGEMENT LLC7,525,929$31.8M
4GEODE CAPITAL MANAGEMENT, LLC3,912,606$16.6M
5MARSHALL WACE, LLP2,037,162$8.6M
6JONES FINANCIAL COMPANIES LLLP1,675,077$7.3M
7VANGUARD PORTFOLIO MANAGEMENT LLC1,462,806$6.2M
8MORGAN STANLEY1,336,293$5.7M
9NORTHERN TRUST CORP1,275,984$5.4M
10VANGUARD FIDUCIARY TRUST CO1,202,839$5.1M
11DAGCO, INC.1,028,780$4.4M
12UBS Group AG745,419$3.2M
13Invesco Ltd.698,080$3.0M
14Nuveen, LLC670,974$2.8M
15BANK OF AMERICA CORP /DE/641,683$2.7M